These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 8136741)

  • 21. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
    Rijnders BJ; Cornelissen JJ; Slobbe L; Becker MJ; Doorduijn JK; Hop WC; Ruijgrok EJ; Löwenberg B; Vulto A; Lugtenburg PJ; de Marie S
    Clin Infect Dis; 2008 May; 46(9):1401-8. PubMed ID: 18419443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group.
    Wolff SN; Fay J; Stevens D; Herzig RH; Pohlman B; Bolwell B; Lynch J; Ericson S; Freytes CO; LeMaistre F; Collins R; Pineiro L; Greer J; Stein R; Goodman SA; Dummer S
    Bone Marrow Transplant; 2000 Apr; 25(8):853-9. PubMed ID: 10808206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Once-weekly liposomal amphotericin B as Candida prophylaxis in very low birth weight premature infants: a prospective, randomized, open-label, placebo-controlled pilot study.
    Arrieta AC; Shea K; Dhar V; Cleary JP; Kukreja S; Morris M; Vargas-Shiraishi OM; Ashouri N; Singh J
    Clin Ther; 2010 Feb; 32(2):265-71. PubMed ID: 20206784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial.
    Davidson RN; Di Martino L; Gradoni L; Giacchino R; Russo R; Gaeta GB; Pempinello R; Scott S; Raimondi F; Cascio A
    Q J Med; 1994 Feb; 87(2):75-81. PubMed ID: 8153291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients.
    Andström EE; Ringdén O; Remberger M; Svahn BM; Tollemar J
    Mycoses; 1996; 39(5-6):185-93. PubMed ID: 8909028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients.
    Fortún J; Martín-Davila P; Moreno S; Barcena R; de Vicente E; Honrubia A; García M; Nuño J; Candela A; Uriarte M; Pintado V
    J Antimicrob Chemother; 2003 Nov; 52(5):813-9. PubMed ID: 14563893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
    Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
    Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haemopoietic cell transplantation of patients with a history of deep or invasive fungal infection during prophylaxis with liposomal amphotericin B.
    Krüger WH; Rüssmann B; de Wit M; Kröger N; Renges H; Sobottka I; Zander AR
    Acta Haematol; 2005; 113(2):104-8. PubMed ID: 15802888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amphotericin B serum levels in pediatric bone marrow transplant recipients.
    Emminger W; Lang HR; Emminger-Schmidmeier W; Peters C; Gadner H
    Bone Marrow Transplant; 1991 Feb; 7(2):95-9. PubMed ID: 2049564
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
    Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
    Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team.
    Alangaden G; Chandrasekar PH; Bailey E; Khaliq Y
    Bone Marrow Transplant; 1994 Dec; 14(6):919-24. PubMed ID: 7711669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT.
    Hebart H; Klingspor L; Klingebiel T; Loeffler J; Tollemar J; Ljungman P; Wandt H; Schaefer-Eckart K; Dornbusch HJ; Meisner C; Engel C; Stenger N; Mayer T; Ringden O; Einsele H
    Bone Marrow Transplant; 2009 Apr; 43(7):553-61. PubMed ID: 19079316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies.
    Mehta J; Kelsey S; Chu P; Powles R; Hazel D; Riley U; Evans C; Newland A; Treleaven J; Singhal S
    Bone Marrow Transplant; 1997 Jul; 20(1):39-43. PubMed ID: 9232254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group.
    Rotstein C; Bow EJ; Laverdiere M; Ioannou S; Carr D; Moghaddam N
    Clin Infect Dis; 1999 Feb; 28(2):331-40. PubMed ID: 10064252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.
    Bowden R; Chandrasekar P; White MH; Li X; Pietrelli L; Gurwith M; van Burik JA; Laverdiere M; Safrin S; Wingard JR
    Clin Infect Dis; 2002 Aug; 35(4):359-66. PubMed ID: 12145716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.
    Queiroz-Telles F; Berezin E; Leverger G; Freire A; van der Vyver A; Chotpitayasunondh T; Konja J; Diekmann-Berndt H; Koblinger S; Groll AH; Arrieta A;
    Pediatr Infect Dis J; 2008 Sep; 27(9):820-6. PubMed ID: 18679151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful bone marrow transplantation in patients with previous invasive fungal infections: report of four cases.
    Martino R; Nomdedéu J; Altés A; Sureda A; Brunet S; Martínez C; Domingo-Albós A
    Bone Marrow Transplant; 1994 Mar; 13(3):265-9. PubMed ID: 8199569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses.
    Wingard JR
    Bone Marrow Transplant; 1997 Feb; 19(4):343-7. PubMed ID: 9051244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective clinical comparison between antifungal treatment with liposomal amphotericin B (AmBisome) and conventional amphotericin B in transplant recipients.
    Tollemar J; Andersson S; Ringdén O; Tydén G
    Mycoses; 1992; 35(9-10):215-20. PubMed ID: 1291871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
    List AF; Maziarz R; Stiff P; Jansen J; Liesveld J; Andrews F; Schuster M; Wolff S; Litzow M; Karanes C; Dahlberg S; Kirkhart B; Bianco JA; Singer JW
    Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.